As several of Takeda’s top-earning drugs veer toward the patent cliff, the Japanese drugmaker is buckling up for a bumpy ride.
Bracing for losses of exclusivity on a pair of drugs this year, Takeda has forecasted 3,840 billion yen (about $28.5 billion) in revenues for fiscal year 2023, an expected 4.7% drop from the sum the company reported in 2022.
